Your browser doesn't support javascript.
loading
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras.
Zhang, Xiaoyu; Luukkonen, Lena M; Eissler, Christie L; Crowley, Vincent M; Yamashita, Yu; Schafroth, Michael A; Kikuchi, Shota; Weinstein, David S; Symons, Kent T; Nordin, Brian E; Rodriguez, Joe L; Wucherpfennig, Thomas G; Bauer, Ludwig G; Dix, Melissa M; Stamos, Dean; Kinsella, Todd M; Simon, Gabriel M; Baltgalvis, Kristen A; Cravatt, Benjamin F.
Afiliación
  • Zhang X; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Luukkonen LM; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Eissler CL; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Crowley VM; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Yamashita Y; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Schafroth MA; Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., 463-10 Kawauchi-cho, Tokushima, 771-0192, Japan.
  • Kikuchi S; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Weinstein DS; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Symons KT; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Nordin BE; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Rodriguez JL; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Wucherpfennig TG; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Bauer LG; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Dix MM; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Stamos D; The Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92307, United States.
  • Kinsella TM; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Simon GM; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Baltgalvis KA; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
  • Cravatt BF; Vividion Therapeutics, 5820 Nancy Ridge Dr, San Diego, California 92121, United States.
J Am Chem Soc ; 143(13): 5141-5149, 2021 04 07.
Article en En | MEDLINE | ID: mdl-33783207
ABSTRACT
Ligand-induced protein degradation has emerged as a compelling approach to promote the targeted elimination of proteins from cells by directing these proteins to the ubiquitin-proteasome machinery. So far, only a limited number of E3 ligases have been found to support ligand-induced protein degradation, reflecting a dearth of E3-binding compounds for proteolysis-targeting chimera (PROTAC) design. Here, we describe a functional screening strategy performed with a focused library of candidate electrophilic PROTACs to discover bifunctional compounds that degrade proteins in human cells by covalently engaging E3 ligases. Mechanistic studies revealed that the electrophilic PROTACs act through modifying specific cysteines in DCAF11, a poorly characterized E3 ligase substrate adaptor. We further show that DCAF11-directed electrophilic PROTACs can degrade multiple endogenous proteins, including FBKP12 and the androgen receptor, in human prostate cancer cells. Our findings designate DCAF11 as an E3 ligase capable of supporting ligand-induced protein degradation via electrophilic PROTACs.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complejos de Ubiquitina-Proteína Ligasa Límite: Humans / Male Idioma: En Revista: J Am Chem Soc Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Complejos de Ubiquitina-Proteína Ligasa Límite: Humans / Male Idioma: En Revista: J Am Chem Soc Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos